Skip to main content
. Author manuscript; available in PMC: 2013 Apr 11.
Published in final edited form as: Immunol Rev. 2011 Nov;244(1):218–231. doi: 10.1111/j.1600-065X.2011.01069.x

Fig. 3. OX40 agonist clinical trial scheme.

Fig. 3

The trial design included 3 dose cohorts with 10 patients treated per dose. As shown in (A), equal numbers of patients within each cohort were randomized into Arm A or B. As shown in (B), patients in Arm A received the reporter antigen KLH on the same day as anti-OX40 administration and tetanus 29 days later, while patients in Arm B received tetanus on the same day as anti-OX40 administration and KLH 29 days later. Anti-OX40 was administered in three separate doses on days 1, 3, and 5, and peripheral blood lymphocytes were isolated at the indicated time points for immune monitoring.